Dermtreat's series A round brings in $17.7M

Mucosal disease company Dermtreat ApS (Copenhagen, Denmark) raised $17.7 million in a series A round led by Sofinnova Ventures. Also participating were Novo Seeds, Lundbeckfonden Emerge and existing shareholders including Welfare Tech Invest.

Dermtreat CEO Jens Hansen told BioCentury the group also includes angel investors and Acerus Pharmaceuticals Corp. (TSX:ASP). The company said it has also received an award from Denmark's Innovationsfonden...